How To Place Bets On Early Oncology Assets
With late-stage assets scarce, Campbell Alliance consultants offer tips for spotting early oncology opportunities, as part of Windhover’s Therapeutic Area Partnerships annual showcase of top unpartnered assets. MEI Pharma, Macrogenics and EnGeneIC are among the companies featured this year.
You may also be interested in...
Every November at Elsevier Business Intelligence’s Therapeutic Area Partnerships meeting in Boston, expert consultants present their pick of the top unpartnered oncology candidates. This year NewLink Genetics, Genelux, and Verastem are among those that made the grade.
Forma has garnered a deal with J&J subsidiary Janssen Pharmaceuticals to develop and commercialize treatments for tumor metabolism.
The German pharma pays $65 million upfront in a deal with high-ceilinged milestones, in an ambitious effort to discover cancer drugs that affect protein-protein interactions.